Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
PENTHRANE (methoxyflurane) is an inhaled volatile anesthetic liquid approved in 1962 for general anesthesia. The mechanism of action involves depression of the central nervous system through interaction with neuronal membranes, producing rapid anesthesia onset and offset. It was historically used for maintenance anesthesia and analgesia across diverse surgical and acute pain settings.
Product is in terminal lifecycle stage with minimal competitive pressure (30) and zero linked job openings, indicating a legacy asset with declining commercial relevance.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PENTHRANE offers no career growth trajectory; the product is a legacy asset with zero linked job openings and minimal commercial activity. Career professionals should avoid assignment to this product unless seeking a wind-down or compliance-focused role.
Worked on PENTHRANE at Abbott? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.